Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ciclesonide Nasal Spray in Pediatric PAR
NCT00261287Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2005
- Primary completion
- Jun 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perennial allergic rhinitis (PAR) comparing Ciclesonide with Placebo (2 arms). Primary endpoint: Safety and tolerability of ciclesonide nasal spray at 12 weeks. Started Nov 2005; status: completed.
02
Drugs
ciclesonide
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00261287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261287.